Glenmark Pharma shines on getting USFDA's nod for Fluticasone Propionate Nasal Spray
Glenmark Pharmaceuticals is currently trading at Rs. 2278.95, up by 23.95 points or 1.06% from its previous closing of Rs. 2255.00 on the BSE.
The scrip opened at Rs. 2255.95 and has touched a high and low of Rs. 2287.65 and Rs. 2255.00 respectively. So far 4547 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 2471.05 on 29-Apr-2026 and a 52 week low of Rs. 1794.00 on 28-Oct-2025.
Last one week high and low of the scrip stood at Rs. 2341.00 and Rs. 2224.00 respectively. The current market cap of the company is Rs. 63952.11 crore.
The promoters holding in the company stood at 46.65%, while Institutions and Non-Institutions held 39.53% and 13.81% respectively.
Glenmark Pharmaceuticals has received USFDA’s approval for Fluticasone Propionate Nasal Spray USP, 0.05 mg/spray. The company’s Fluticasone Propionate Nasal Spray USP is bioequivalent and therapeutically equivalent to the reference listed drug, Flonase Nasal Spray, 0.05 mg/spray of Haleon US Holdings LLC (NDA 020121) and will be distributed in the U.S. by Glenmark Pharmaceuticals Inc., USA.
According to IQVIA sales data for the 12-month period ending June 2026, the Flonase Nasal Spray market achieved annual sales of around $295.2 million.
